Articles published by Pfizer Inc.
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 02, 2024
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
December 19, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Declares First-Quarter 2024 Dividend
December 14, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Completes Acquisition of Seagen
December 14, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Provides Full-Year 2024 Guidance
December 13, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
December 12, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
December 11, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
December 09, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
December 08, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
December 01, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 21, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting
November 02, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 02, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Reports Third-Quarter 2023 Results
October 31, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance
October 13, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
October 13, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
October 12, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Declares Fourth-Quarter 2023 Dividend
October 04, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV
September 22, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 19, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
September 19, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts
September 18, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 12, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
September 11, 2023
From Pfizer Inc.
Via Business Wire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 05, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.